JournalClinical Breast Cancer
MetadataShow full item record
AbstractBreast cancer management has progressed immensely over the decades, but the disease is still a major source of morbidity and mortality worldwide. Even with enhanced imaging detection and tissue biopsy capabilities, disease can progress on an ineffective treatment before additional information is obtained through standard methods of response evaluation, including the RECIST 1.1 criteria, widely used for assessment of treatment response and benefit from therapy.6 Circulating biomarkers have the potential to provide valuable insight into disease progression and response to therapy, and they can serve to identify actionable mutations and tumor characteristics that can direct therapy. These biomarkers can be collected at higher frequencies than imaging or tissue sampling, potentially allowing for more informed management. This review will evaluate the roles of circulating biomarkers in breast cancer, including the serum markers Carcinoembryonic antigen CA15-3, CA27-29, HER2 ECD, and investigatory markers such as GP88; and the components of the liquid biopsy, including circulating tumor cells, cell free DNA/DNA methylation, circulating tumor DNA, and circulating microRNA.
Rights/TermsCopyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17186
- Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer.
- Authors: Tkaczuk KHR, Hawkins D, Yue B, Hicks D, Tait N, Serrero G
- Issue date: 2020 Jun
- An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
- Authors: Perrier A, Boelle PY, Chrétien Y, Gligorov J, Lotz JP, Brault D, Comperat E, Lefèvre G, Boissan M
- Issue date: 2020
- Crucial considerations for pipelines to validate circulating biomarkers for breast cancer.
- Authors: Ewaisha R, Gawryletz CD, Anderson KS
- Issue date: 2016
- CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
- Authors: Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, Robertson JF
- Issue date: 2001 Feb
- Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
- Authors: Hou MF, Chen YL, Tseng TF, Lin CM, Chen MS, Huang CJ, Huang YS, Hsieh JS, Huang TJ, Jong SB, Huang YF
- Issue date: 1999 Sep